- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 1611493-60-7] Bictegravir
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-17605 |
| Brand: | MCE |
| CAS: | 1611493-60-7 |
Overview
| MDL | MFCD31536971 |
|---|---|
| Molecular Weight | 449.38 |
| Molecular Formula | C21H18F3N3O5 |
| SMILES | O=C1N([C@](CC2)([H])C[C@]2([H])O3)[C@@]3([H])CN(C=C(C(NCC(C(F)=CC(F)=C4)=C4F)=O)C5=O)C1=C5O |
6 Publications Citing Use of MCE
Summary
Bictegravir (GS-9883) is a potent inhibitor of HIV-1 integrase with an IC 50 of 7.5 nM.
IC50 & Target
IC50: 7.5 nM (HIV-1 integrase) [1]
In Vitro
Bictegravir (BIC) inhibits the strand transfer activity with an IC 50 of 7.5± 0.3 nM. Relative to its inhibition of strand transfer activity, Bictegravir is a much weaker inhibitor of 3′-processing activity of HIV-1 IN, with an IC 50 of 241±51 nM. Bictegravir enhances the accumulation of 2-LTR circles ~5-fold relative to the mock-treated control and reduces the amount of authentic integration products in infected cells by 100-fold. Bictegravir potently inhibits HIV-1 replication in both MT-2 and MT-4 cells with EC 50 s of 1.5 and 2.4 nM, respectively. Bictegravir exhibits potent antiviral effects in both primary CD4 + T lymphocytes and monocyte-derived macrophages, with EC 50 s of 1.5±0.3 nM and 6.6±4.1 nM, respectively, which are comparable to values obtained in T-cell lines [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT04518228 | National Institute of Allergy and Infectious Diseases (NIAID)|International Maternal Pediatric Adolescent AIDS Clinical Trials Group|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Mental Health (NIMH)|Gilead Sciences|ViiV Healthcare|Merck Sharp & Dohme LLC |
HIV Infections|Tuberculosis
|
June 8, 2021 | |
| NCT02400307 | Gilead Sciences |
HIV
|
April 17, 2015 | Phase 1 |
| NCT03711253 | University of Southern California |
Acute HIV Infection
|
October 14, 2019 | Phase 4 |
| NCT05502341 | Gilead Sciences |
HIV-1-infection
|
August 16, 2022 | Phase 2|Phase 3 |
| NCT04054089 | Cristina Mussini|University of Modena and Reggio Emilia |
HIV Infections
|
September 2019 | Phase 4 |
| NCT03499483 | Fenway Community Health |
HIV Prevention
|
January 24, 2019 | Phase 4 |
| NCT04712058 | National Taiwan University Hospital|Far Eastern Memorial Hospital|Mackay Memorial Hospital|Changhua Christian Hospital|Chung Shan Medical University|National Cheng-Kung University Hospital|Chi Mei Medical Hospital|Kaohsiung Medical University Chung-Ho Memorial Hospital|Kaohsiung Municipal Ta-Tung Hospital |
HIV Infections
|
January 20, 2021 | Not Applicable |
| NCT04805944 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
HIV Infections
|
March 5, 2021 | |
| NCT02275065 | Gilead Sciences |
HIV-1 Infection
|
October 24, 2014 | Phase 1 |
| NCT04853524 | Janssen Research & Development, LLC |
Healthy
|
May 6, 2021 | Phase 1 |
| NCT04585737 | Charlotte-Paige Rolle, MD|ViiV Healthcare|Orlando Immunology Center |
HIV I Infection
|
September 22, 2020 | Phase 4 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
DMSO : 83.3 mg/mL ( 185.37 mM ; Need ultrasonic and warming)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.2253 mL | 11.1264 mL | 22.2529 mL |
| 5 mM | 0.4451 mL | 2.2253 mL | 4.4506 mL |
| 10 mM | 0.2225 mL | 1.1126 mL | 2.2253 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (5.56 mM); Clear solution
-
3.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (5.56 mM); Clear solution
-
4.
Add each solvent one by one: 5% DMSO >> 95% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (5.56 mM); Clear solution
Synonyms
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.